Please assess the completion status of the following clinical trial:

Trial Title: SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathology confirmed biliary malignancy, including intrahepatic bile duct carcinoma, extrahepatic bile duct carcinoma, and gallbladder carcinoma.~* Age:18-75 years, male or female.~* The estimated survival period is more than 3 months.~* ECOG 0-1.~* There is at least one measurable lesion, according to the RECIST 1.1 standard.~* Patients has not been treated by oxaliplatin, gemcitabine and pd-1 / pd-l1 antibody.~* Patients who have been treated tegafur or capecitabine as adjuvant chemotherapy or first-line treatment may be selected.~Exclusion Criteria:~* There were concurrent malignant tumors, except for the cured skin basal cell carcinoma and cervical carcinoma in situ.~* Other drug clinical trials have been taken in four weeks.~* Patients with a history of central nervous system metastasis or central nervous system metastasis are known before the screening.~* Patients with a history of unstable angina.~* The urine routine indicated that the urine protein was greater than ++ and confirmed the 24-hour urine protein quantification \>1.0 g.~* Have used immune-targeted therapy drugs.~* The patient had received a liver transplant.~* Having a history of chronic autoimmune diseases such as systemic lupus erythematosus.~* Having a history of immunodeficiency, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SHR1210+GEMOX (Type: EXPERIMENTAL): This is a single arm trial. Participants will receive SHR1210 + GEMOX treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).